Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dolutegravir + lamivudine versus dolutegravir + tenofovir/emtricitabine in treatment-naive adults with HIV-1
NL-OMON50555Phase 3Active, not recruiting
- Sponsor
- ViiV Healthcare
- Start
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of dolutegravir, lamivudine, tenofovir disoproxil fumarate and emtricitabine, sponsored by ViiV Healthcare. Started Dec 2016; status: active, not recruiting.
02
Drugs
dolutegravirlamivudinetenofovir disoproxil fumarateemtricitabine
Beyond the preview
Go deeper on NL-OMON50555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50555.